The 65.4% Stake of China Cord Blood Corp. (CO) Held by Golden Meditech Stem Cells (BVI) Company Limited

The 65.4% Stake of China Cord Blood Corp. (CO) Held by Golden Meditech Stem Cells (BVI) Company Limited

Golden Meditech Stem Cells (BVI) Company Limited recently revealed that they own a 65.4% stake in China Cord Blood Corp. (NYSE:CO) in a Form 13D/A disclosure that was filed with the Securities and Exchange Commission on Monday, October 31st. The investor owns 78,874,106 shares of the stock valued at about $395,948,012. The reporting parties listed on the disclosure included Golden Meditech Stem Cells (BVI) Company Limited, Golden Meditech Holdings Limited, Bio Garden Inc and Yuen Kam. The filing is available through Edgar at this link.

Several other hedge funds and other institutional investors have also made changes to their positions in CO. State Street Corp increased its position in China Cord Blood Corp. by 2.7% in the second quarter. State Street Corp now owns 28,995 shares of the company’s stock valued at $167,000 after buying an additional 762 shares in the last quarter. Panagora Asset Management Inc. increased its position in China Cord Blood Corp. by 5.2% in the second quarter. Panagora Asset Management Inc. now owns 186,430 shares of the company’s stock valued at $1,072,000 after buying an additional 9,187 shares in the last quarter. Finally, GLG Partners LP increased its position in China Cord Blood Corp. by 2.2% in the second quarter. GLG Partners LP now owns 923,931 shares of the company’s stock valued at $5,313,000 after buying an additional 19,800 shares in the last quarter. Hedge funds and other institutional investors own 9.16% of the company’s stock.

Shares of China Cord Blood Corp. (NYSE:CO) opened at 5.02 on Monday. The firm has a 50 day moving average price of $5.09 and a 200-day moving average price of $5.57. The firm has a market capitalization of $366.48 million, a P/E ratio of 26.70 and a beta of 0.45. China Cord Blood Corp. has a 52 week low of $4.52 and a 52 week high of $6.51.

China Cord Blood Corp. (NYSE:CO) last released its earnings results on Monday, August 22nd. The company reported $0.03 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.03. The business had revenue of $26 million for the quarter, compared to analyst estimates of $26.23 million. China Cord Blood Corp. had a return on equity of 5.85% and a net margin of 13.90%. Equities research analysts predict that China Cord Blood Corp. will post $0.15 EPS for the current fiscal year.

Several research firms recently commented on CO. Zacks Investment Research downgraded China Cord Blood Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, July 19th. TheStreet downgraded China Cord Blood Corp. from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. One investment analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $6.75.

China Cord Blood Corp. Company Profile

China Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People’s Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee.

Related posts

Leave a Comment